Prolactin

Prolactin (PRL) is a 23-kDa protein hormone primarily produced by lactotroph cells in the anterior pituitary gland, although it is also synthesized in various peripheral tissues. Researchers primarily study prolactin for its crucial role in regulating lactation and its involvement in reproductive functions. Key findings indicate that prolactin signaling is mediated through its unique receptor (PRLR) and the JAK2/Stat5 pathway, with emerging evidence linking prolactin to a variety of biological processes, including behavior, metabolic regulation, and immune responses. Additionally, studies suggest that extrapituitary sources of prolactin may have distinct physiological roles, particularly in pregnancy and lactation. Current research continues to explore the multifaceted actions of prolactin, with clinical evidence indicating its potential implications in conditions such as breast cancer and metabolic disorders.

Prolactin (PRL), also known as Luteotropin or Luteotropic Hormone, is an endogenous hormone primarily synthesized and secreted by lactotroph cells in the anterior pituitary gland. It is a 23-kDa protein, although it can also be produced in smaller amounts by various peripheral tissues. PRL belongs to the category of pituitary and trophic hormones. Researchers have found that prolactin plays a crucial role in regulating reproductive functions, particularly in lactation and normal reproduction in rodents. Beyond its reproductive roles, prolactin is involved in a variety of biological processes, including behavior modulation, metabolic homeostasis, and immune responses. It has also been implicated in conditions such as migraines, inflammatory diseases, and certain cancers. Prolactin exerts its effects by binding to the prolactin receptor (PRLR), which activates the JAK2/Stat5 signaling pathway. This pathway is considered the primary mechanism for PRL's actions, although other pathways may also be involved. The hormone can be cleaved into a shorter form, vasoinhibin, whose signaling mechanisms are not fully understood. Pharmacokinetic properties of prolactin, such as half-life and bioavailability, are not well-documented in the literature. Prolactin's clinical use is primarily in the context of research, with some studies exploring its role in breast cancer therapy. Regulatory standing varies by region, with no specific therapeutic formulations widely approved for clinical use.

Prolactin acts primarily through the prolactin receptor (PRLR), which is a transmembrane receptor. Upon binding, PRL activates the JAK2/Stat5 signaling pathway, leading to various biological effects, including regulation of reproductive and immune functions.

Prolactin (PRL) primarily exerts its effects through binding to the prolactin receptor (PRLR), activating the JAK2/STAT5 signaling pathway, which mediates various biological processes including lactation, reproduction, and maternal behavior. Additionally, PRL can be cleaved into a shorter form, vasoinhibin, although its signaling mechanisms remain less well understood. PRL is also implicated in diverse functions such as metabolic homeostasis, inflammation, and cancer, highlighting its complex role in both physiological and pathophysiological contexts.

Current evidence is limited regarding the specific signaling mechanisms of the cleaved 16-kDa prolactin (vasoinhibin) and its distinct physiological roles compared to full-length prolactin. Further research is needed to clarify the divergent actions of pituitary versus extrapituitary prolactin, particularly in human populations, as existing studies often yield conflicting results. Additionally, larger randomized controlled trials (RCTs) are necessary to explore the therapeutic potential of prolactin receptor antagonists in various diseases, including breast and prostate cancer, and to assess their efficacy across different demographic groups.